Ono-3307 mesylate
| Code | Size | Price |
|---|
| TAR-T28248-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28248-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28248-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ono-3307 is a protease inhibitor potentially for the treatment of thrombosis. ONO-3307 competitively inhibited trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein and chymotrypsin; and their Ki values were 0.048 microM, 0.18 microM, 0.29 microM, 0.31 microM, 3.6 microM and 47 microM, respectively. In addition, ONO-3307 inhibited both elastase release from N-formyl-Met-Leu-Phe (fMLP)-stimulated leukocytes and tissue thromboplastin release from endotoxin-stimulated leukocytes. ONO-3307 exhibits a wide range of inhibitory effects on various proteases, and ONO-3307 may be useful for the treatment of protease-mediated diseases such as thrombosis and DIC.
CAS:
76472-29-2
Formula:
C15H18N4O7S2
Molecular Weight:
430.45
Purity:
0.98
SMILES:
CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc(cc1)S(N)(=O)=O
References
1. Hirano T, Manabe T, Steer M, Printz H, Calne R, Tobe T. Protective effects of therapy with a protease and xanthine oxidase inhibitor in short form pancreatic biliary obstruction and ischemia in rats. Surg Gynecol Obstet. 1993 Apr;176(4):371-81. PubMed PMID: 8460415.
2. Sobajima H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Ishiguro H, Tanikawa M, Nakae Y. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats. Pancreas. 1993 Mar;8(2):240-7. PubMed PMID: 8460097.
3. Ono S, Tamakuma S, Mochizuki H, Kinoshita M, Ohkusa Y, Aosasa S, Oda Y, Ohe H. Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Surg Today. 1993;23(3):228-33. PubMed PMID: 8467174.
4. Hirano T, Manabe T, Tobe T. Impaired hepatic energy metabolism in rat acute pancreatitis: protective effects of prostaglandin E2 and synthetic protease inhibitor ONO 3307. J Surg Res. 1992 Sep;53(3):238-44. PubMed PMID: 1528049.